⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PPCB News
Propanc Biopharma, Inc. Common Stock
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
businesswire.com
PPCB
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
businesswire.com
PPCB
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
globenewswire.com
PPCB
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
globenewswire.com
PPCB
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
globenewswire.com
PPCB
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
globenewswire.com
PPCB
Form 8-K
sec.gov
PPCB
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
globenewswire.com
PPCB
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
globenewswire.com
PPCB
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
globenewswire.com
PPCB